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Arterial Ultrasonography and Tonometry
as Adjuncts to Cardiovascular Risk Stratification
Iftikhar J. Kullo, MD, FACC, A. Rauoof Malik, MD
Rochester, Minnesota
Myocardial infarction and stroke often occur without prior warning in asymptomatic individuals. Identifying indi-
viduals at risk is important for cost-effective use of preventive therapies. Algorithms based on risk factors statis-
tically associated with cardiovascular events classify individuals into high-risk, intermediate-risk, or low-risk cate-
gories. However, more than one-third of adults in the U.S. are in the intermediate-risk category, and decisions
regarding therapy are challenging in this subset. Testing for alterations in arterial function and structure that
predate cardiovascular events may help refine cardiovascular risk assessment in the intermediate-risk group and
identify candidates for aggressive therapy. Vascular ultrasonography and tonometry are promising test modali-
ties for assessment of arterial function and structure in asymptomatic subjects. Several prospective studies have
shown that measures of arterial function and structure provide prognostic information incremental to conven-
tional risk factors. Standardization of methodology and establishment of quality control standards in the perfor-
mance of these tests could facilitate their integration into clinical practice as adjuncts to existing cardiovascular
risk stratification algorithms. (J Am Coll Cardiol 2007;49:1413–26) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.039r
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tvery year, 1.2 million Americans suffer a coronary event
approximately 1 event every 26 s and 1 death every min)
nd 700,000 develop a stroke (approximately 1 event every
5 s, causing 1 death every 3 min) (1). These events are most
ften related to atherosclerotic vascular disease and fre-
uently occur without warning (2). Assessment of conven-
ional risk factor burden is necessary but may not accurately
stimate risk of cardiovascular disease (3). Most patients in
hom myocardial infarction or ischemic stroke develops
ave one or more conventional risk factors for atheroscle-
osis, but these risk factors are also prevalent in the general
opulation. As a result, the predictive value of algorithms
ased on conventional risk factors is unsatisfactory (4,5).
early 40% of adults in the U.S. may be at intermediate risk
or a future cardiovascular event when assessed with current
lgorithms (6), and these individuals may benefit from
urther risk stratification. The available screening and diag-
ostic tests have limitations; cardiac stress tests detect only
dvanced, hemodynamically significant lesions, and conven-
ional coronary angiography is invasive, provides only a
luminogram,” and does not identify vulnerable or unstable
laque. Tests for early detection of atherosclerotic vascular
isease are therefore needed to better assess cardiovascular
rom the Division of Cardiovascular Diseases, Mayo Clinic and Foundation,
ochester, Minnesota. This work was supported by grant RR17720 from the
ational Center for Research Resources, National Institutes of Health, Bethesda,
aryland.f
Manuscript received August 11, 2006; revised manuscript received November 22,
006, accepted November 27, 2006.isk in asymptomatic individuals, the main focus of primary
revention.
Noninvasive arterial testing for cardiovascular risk assess-
ent is based on several important considerations. Alter-
tions in arterial function and structure predate clinical
anifestations of occlusive atherosclerotic disease; changes
end to be widespread and are not limited to a single arterial
ed. These alterations result from the cumulative effects of
nown and unknown vascular risk factors that promote
ormation and progression of atherosclerotic lesions and
ay also increase the propensity for atherosclerotic plaque
upture (Fig. 1). Identification of such abnormalities in
ccessible peripheral arteries provides a means for early
etection of presymptomatic vascular disease and improved
ardiovascular risk stratification.
Arterial ultrasonography and tonometry are attractive
odalities for detecting early disease because they are
oninvasive and relatively inexpensive. High-resolution ul-
rasonography can assess arterial dilatation in response to
hear stress or pharmacological stimuli (a function that may
e compromised early in atherogenesis) and directly exam-
ne the arterial wall for early atherosclerotic changes pre-
eding luminal compromise. Arterial tonometry can be used
o acquire arterial pulse waveforms to assess arterial stiffness
nd wave reflection, measures that have been associated
ith the presence and extent of atherosclerotic vascular
isease and cardiovascular events. In this article, we review
he potential use of vascular ultrasonography and tonometry
or noninvasive assessment of arterial function and structure
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Arterial Ultrasonography and Tonometry April 3, 2007:1413–26as adjuncts to cardiovascular risk
stratification. Although ultra-
sonography and tonometry have
been used in research settings to
investigate the effect of risk fac-
tors and risk factor intervention
on arterial function, this review
focuses on their potential clinical
utility in cardiovascular risk
assessment.
Ultrasonography to Assess
Conduit Artery and
Microcirculatory Function
Functional abnormalities of the
endothelium precede develop-
ent of atherosclerotic plaque and may also be involved in
ts progression and clinical expression (7,8). Endothelial
ysfunction reflects the cumulative effect of conventional
nd novel risk factors for atherosclerosis. A key feature of
ndothelial dysfunction is reduced bioavailability of nitric
xide, an endothelium-derived vasodilator with antiathero-
enic properties (9). Arterial vasodilatation in response to
hear stress produced by increased flow is mediated predom-
nantly by endothelium-derived nitric oxide (10,11), and
ence, flow-mediated dilatation (FMD) is considered a
iomarker of endothelial function (12,13). At present,
MD is commonly assessed by high-resolution ultrasonog-
aphy of the brachial artery.
Because endothelial dysfunction is associated with car-
iovascular events (14), measurement of brachial artery
Abbreviations
and Acronyms
AIx  aortic augmentation
index
aPWV  aortic pulse wave
velocity
BP  blood pressure
CHD  coronary heart
disease
FMD  flow-mediated
dilatation
IMT  intima-media
thickness
PWV  pulse wave velocity
Figure 1 Association of Altered Arterial Function and
Structure With Cardiovascular Events
Functional and structural abnormalities in the arterial wall caused by conven-
tional, novel, and genetic risk factors promote the development of atheroscle-
rotic plaque. Functional abnormalities in the arterial wall may favor progression
of nonobstructive plaques to more advanced, flow-limiting lesions. Additionally,
such changes may increase the propensity of atherosclerotic plaque to fissur-
ing and rupture, thereby precipitating acute cardiovascular events.aMD may help to identify patients at risk. The prognostic
alue of brachial artery FMD has been shown in several
atient populations (15–24) (Table 1). Chan et al. (20)
howed that in patients with coronary heart disease (CHD),
mpaired baseline FMD and its further decrease over time
redicted the occurrence of adverse cardiovascular events. In
atients with peripheral arterial disease, impaired FMD was
redictive of early and late adverse cardiovascular events
fter vascular surgery, even after accounting for risk factors
nd the ankle-brachial index (16,18). In patients undergo-
ng evaluation for chest pain, impaired FMD was predictive
f adverse cardiac events in the near term and long term
15). Two recent studies (23,24) showed FMD to be
redictive of increased mortality and the need for cardiac
ransplantation in patients with congestive heart failure.
Data about the incremental prognostic value of FMD in
symptomatic subjects are limited. In a study of 444 subjects
t increased cardiovascular risk (21), the incidence of ad-
erse cardiovascular events and all-cause mortality over a
edian follow-up period of 2 years was significantly higher
n subjects with FMD 2% compared with those with
MD 2%. However, FMD was not an independent
redictor of these events after adjustment for conventional
isk factors. Whether an improvement in FMD translates
nto improved clinical outcome is yet to be established,
lthough in a study of 400 hypertensive postmenopausal
omen, failure to improve FMD after 6 months of optimal
ntihypertensive therapy was associated with increased risk
f nonfatal cardiovascular events over a mean follow-up of
7 months (17).
In addition to FMD, brachial artery ultrasound also
rovides a means of assessing other measures of arterial
unction that may be associated with cardiovascular risk. For
xample, impaired brachial artery dilatation to sublingually
dministered nitroglycerin, an “endothelium-independent”
esponse that reflects arterial smooth muscle function (25),
as been noted to be impaired in the presence of cardiovas-
ular disease (26,27) as well as in asymptomatic subjects
ith risk factors (28,29). Brachial artery ultrasound can be
ombined with pulsed Doppler to measure forearm blood
ow at rest and during the phase of hyperemia after
ransient forearm occlusion; both measures reflect microvas-
ular function. Several cardiovascular risk factors have been
ound to be associated with higher resting forearm blood
ow (30,31) and a blunted reactive hyperemic response
31–33). Postischemic reactive hyperemia is mainly medi-
ted by local release of ischemia-induced vasodilator sub-
tances from forearm resistance vessels (34,35), although
yogenic response (36) and endothelial nitric oxide (32,37)
ikely play a role. Further studies are needed to investigate
hether nitroglycerin-mediated dilatation of the brachial
rtery and reactive hyperemia in the forearm are associated
ith increased cardiovascular risk.
Thus, arterial dysfunction related to atherosclerosis
nd its risk factors may manifest as impaired conduit
rtery responsiveness to endothelium-dependent and
Studies Investigating the Association of Brachial Arterial Flow-Mediated Dilatation With Cardiovascular Events
Table 1 Studies Investigating the Association of Brachial Arterial Flow-Mediated Dilatation With Cardiovascular Events
Reference Study Sample Follow-Up End Points Assessed Risk Estimate (95% Confidence Interval) Conclusion
Neunteufl et al. (15) 73 patients (51 yrs)* with
chest pain
5 yrs Death, CHD events FMD 10% had PPV of 52% and NPV of 85% Preserved FMD in patients with chest pain was
predictive of low risk of CHD events.
Gokce et al. (16) 187 patients (65 yrs)*
undergoing vascular
surgery
1 month Fatal and nonfatal CHD
events, stroke
Adjusted OR for FMD 8.1% vs. 8.1% was
9.0 (1.2–68); PPV 32%, NPV 92%
Impaired FMD was an independent predictor
of postoperative CV events.
Modena et al. (17) 400 hypertensive
postmenopausal
women (57 yrs)*
67 months Nonfatal CV events needing
hospitalization
Adjusted incidence rate ratio for women with
FMD 10% after 6 months vs. those with
FMD 10%  7.3 (3.8–14.2)
Failure to improve FMD after 6 months of
antihypertensive therapy was an
independent predictor of CV events.
Gokce et al. (18) 199 patients (66 yrs)*
undergoing vascular
surgery
1.2 yrs Fatal and nonfatal CHD
events, stroke
Adjusted OR for FMD 8.1% vs. 8.1% 
9.5 (2.3–40)
Impaired FMD was an independent predictor
of CV events.
Brevetti et al. (19) 131 patients (64 yrs)*
with PAD
23 months Fatal and nonfatal CHD,
cerebrovascular or
peripheral vascular events
RR for FMD, ABI, or both  median vs. both
 median  4.8 (1.1–23.3), 6.4
(1.4–29.1), and 13.0 (3.0–56.1),
respectively
FMD and ABI had additive prognostic value for
prediction of CV events.
Chan et al. (20) 152 patients (56 yrs) with
CHD
34 months Fatal or nonfatal CHD,
cerebrovascular or
peripheral vascular events
Baseline FMD/NMD ratio (p  0.0001) and
change in FMD (p  0.05) on follow-up
were associated with CV events
Lower FMD and decrease in FMD over time
were independently predictive of CV events.
The predictive values of FMD and carotid
plaque were additive.
Fathi et al. (21) 444 patients (58 yrs) at
high risk of CHD
24 months (median) Fatal and nonfatal CHD
events, stroke
Event rate was higher in patients with FMD
2% vs. those with FMD 2% but not
after adjustment for baseline risk
FMD was lower for patients with CV events but
not an independent predictor of events.
Frick et al. (22) 398 men (54 yrs) with
chest pain
39 months Fatal or nonfatal CHD events Event-free survival for patients with FMD 
median was not different from those with
FMD  median (p  0.47)
FMD was not independently predictive of CHD
events.
Meyer et al. (23) 75 CHF patients (56 yrs),*
UNOS status 2
Up to 3 yrs Conversion to UNOS status 1
or death
FMD predicted combined end point after
adjustment for functional class, beta-
blocker use, mean BP, and brain
natriuretic peptide levels (p  0.0007)
Impaired FMD was independent predictor of
conversion to UNOS status 1 or death.
Katz et al. (24) 149 CHF patients (54 yrs),
NYHA functional class
II–III
28 months (median) Death, urgent cardiac
transplantation
Adjusted HR was 1.2 (1.03–1.45) for each
1% decrease in FMD
Lower FMD was associated with higher
mortality risk after adjustment for known
prognostic factors.
Mean age (in parentheses) and follow-up are shown unless indicated otherwise. *The mean age was calculated as the weighted mean of the groups because the overall mean age was not reported in the original study.
ABI  ankle-brachial index; BP  blood pressure; CHD  coronary heart disease; CHF  congestive heart failure; CV  cardiovascular; FMD  flow-mediated dilatation; HR  hazard ratio; IMT  intima-media thickness; NMD  nitroglycerin-mediated dilatation; NPV 
negative predictive value; NYHA  New York Heart Association; OR  odds ratio; PAD  peripheral arterial disease; PPV  positive predictive value; RR  relative risk; UNOS  United Network of Organ Sharing.
1415
JACC
Vol.49,No.13,2007
Kullo
and
M
alik
April3,2007:1413–26
ArterialUltrasonography
and
Tonom
etry
e
c
m
u
a
o
i
a
d
i
r
a
e
a
a
U
S
C
T
i
p
t
c
l
r
u
f
I
a
r
d
d
t
d
b
b
s
v
d
p
u
k
v
r
l
p
A
m
h
1
r
r
0
a
i
a
C
f
c
m
b
t
r
f
S
c
c
i
e
a
a
r
t
t
6
w
r
l
a
U
a
F
h
r
g
t
c
a
c
a
(
c
a
s
p
s
e
e
S
b
p
(
t
a
d
1416 Kullo and Malik JACC Vol. 49, No. 13, 2007
Arterial Ultrasonography and Tonometry April 3, 2007:1413–26ndothelium-independent stimuli as well as reduced mi-
rovascular reactivity. Assessment of conduit artery and
icrocirculatory function using ultrasonography could be
seful in refining cardiovascular risk estimates, choosing
ppropriate risk-reduction therapy, and assessing the effect
f therapeutic interventions. However, brachial vasoreactiv-
ty testing has significant test-to-test variability and requires
skilled ultrasonography technician. Although edge-
etection software may improve precision and reproducibil-
ty and decrease dependence on operator skill (38,39), there
emains a need for standardizing of measurement technique
cross laboratories and establishing cutoff values that differ-
ntiate normal from abnormal. Prospective studies that
ssess the independent predictive value of brachial vasore-
ctivity testing in asymptomatic subjects are awaited.
ltrasonography For Assessing
ubclinical Atherosclerosis:
arotid Intima-Media Thickness (IMT)
he combined thickness of carotid artery intima and media
s measured noninvasively by high-resolution ultrasonogra-
hy. Although atherosclerosis is predominantly a disease of
he intima, carotid IMT correlates with the degree of
arotid atherosclerosis measured at autopsy (40), and the
atter, in turn, has been found to correlate with atheroscle-
otic vascular disease in other arterial beds (41). Thus,
ltrasound-derived carotid IMT is considered a surrogate
or systemic atherosclerotic disease burden. In addition to
MT, carotid ultrasonography also provides information
bout the presence of plaque, lumen stenosis, and arterial
emodeling. Increased carotid IMT is associated with car-
iovascular risk factors (42,43), prevalent cardiovascular
isease (44,45), coronary artery calcification on computed
omography (46), presence and extent of angiographically
etermined coronary atherosclerosis (47,48), and plaque
urden on intracoronary ultrasound (49). Carotid IMT has
een used in research settings to identify patients with
ubclinical atherosclerosis and as an intermediate outcome
ariable in epidemiologic studies and intervention trials of
isease progression (50–53).
Several studies show that increased carotid IMT is
redictive of cardiovascular events in asymptomatic individ-
als (54–59) (Table 2) and recurrent events in patients with
nown cardiovascular disease (60,61), independent of con-
entional risk factors. Increased IMT was associated with
isk of myocardial infarction, stroke, and death in several
arge prospective studies with different study designs, sam-
le characteristics, and IMT measurement protocols. In the
RIC (Atherosclerosis Risk in Communities) study (55), a
ean carotid IMT of 1.0 mm was associated with a
azard ratio for incident CHD events of 5.07 in women and
.85 in men. After adjustment for risk factors, the hazard
atio associated with increased IMT was attenuated but
emained statistically significant. In another study (54), a
.1-mm increase in common carotid artery IMT was mssociated with an 11% increase in the risk of myocardial
nfarction, and the association remained significant after
djustment for several cardiovascular risk factors. In the
ardiovascular Health Study (56), 4,476 subjects were
ollowed over a median period of 6.2 years, and the baseline
arotid IMT was associated with cumulative survival free of
yocardial infarction or stroke. For a 1-SD increase in
aseline IMT, the age- and gender-adjusted relative risk for
he combined end point increased by 35% to 44% and
emained significantly elevated after adjustment for risk
actors. In CAPS (Carotid Atherosclerosis Progression
tudy) (59), 5,056 members of a German primary health
are scheme were followed for a mean of 4.2 years. A higher
ommon carotid IMT was associated with increased risk of
ncident myocardial infarction, stroke, and the combined
nd point of myocardial infarction, stroke, or death even
fter adjustment for conventional risk factors.
Given that carotid IMT is associated with coronary
therosclerosis and cardiovascular events, it may be useful in
efining risk stratification of individual patients, especially
hose assigned to an intermediate-risk category. A limita-
ion of the Framingham cardiovascular risk equations (62–
4) is that these are heavily influenced by patient age
ithout taking into account the heterogeneity of atheroscle-
otic burden. Researchers have proposed replacing chrono-
ogical age in the Framingham risk algorithms with vascular
ge derived from the composite carotid IMT score (65–67).
sing such an approach, nearly one-half of the individuals
ssigned to the intermediate-risk category by the original
ramingham CHD risk algorithm were reclassified into
igher- or lower-risk categories (65). Computerized algo-
ithms may be used to integrate IMT values with demo-
raphic and other relevant clinical information to determine
he vascular age of the individual and recalculate the
ardiovascular risk (65).
The reported median values of carotid IMT have varied,
lthough a value of 1.2 mm or higher for an adult would be
onsidered clearly abnormal (68,69). Progression of IMT in
symptomatic individuals is estimated to be0.03 mm/year
4), but this rate is accelerated in the presence of cardiovas-
ular risk factors (70–72). A higher progression rate is
ssociated with increased risk of myocardial infarction and
troke (55,56,73,74); therefore, serial measurements may
rovide greater prognostic information than a single mea-
urement.
Distinct from diffuse intimal-medial thickening is ath-
rosclerotic plaque, which is typically seen as a focal thick-
ning often with mineralization and protrusion into lumen.
ome studies suggest that plaque area or volume may be a
etter predictor of cardiovascular events than IMT (74–77),
articularly in diabetics (78,79), but the evidence is mixed
58,80). Although carotid IMT needs to be interpreted in
he context of age and gender of an individual, presence of
carotid plaque is always abnormal. However, plaques
evelop late in atherogenesis (81), whereas IMT can be
easured at any age and may be a better marker of systemic
Studies Investigating the Association of Carotid IMT With Cardiovascular Events in Asymptomatic Subjects
Table 2 Studies Investigating the Association of Carotid IMT With Cardiovascular Events in Asymptomatic Subjects
Reference Study Sample Follow-Up End Points Assessed Risk Estimate (95% Confidence Interval) Conclusion
Salonen et al. (54) 1,257 middle-aged eastern
Finnish men
1 month to 2.5 yrs Fatal and nonfatal MI A 0.1-mm increase in IMT was associated with an 11%
(6%–16%) increase in risk; the association
remained significant after adjustment for several
risk factors
Presence of increased carotid IMT or plaque was
associated with increased risk of MI.
Chambless et al. (55) 12,841 subjects (45–64 yrs) 4–7 yrs Fatal and nonfatal CHD events For IMT 1 vs. 1 mm, HR adjusted for age, race, and
study center  1.8 (1.3–2.7) in men and 5.1
(3.1–8.4) in women; the strength of association
was attenuated but remained significant
after adjustment for CV risk factors
Higher baseline IMT was associated with
increased risk of CHD events in both men
and women.
O’Leary et al. (56) 4,476 subjects (65 yrs) 6.2 yrs (median) MI, stroke, combined end
point (MI or stroke)
RR of the combined end point (adjusted for age,
gender, SBP, DBP, smoking, diabetes, and presence
of atrial fibrillation): 3.2 (2.2–4.5) for the highest vs.
the lowest quintile of IMT; similar results for MI and
stroke considered separately
Increased carotid IMT was independently
predictive of MI and stroke in older adults.
Iglesias del Sol et al. (57) 2,073 subjects (55 yrs) 4.6 yrs Fatal and nonfatal MI RR (adjusted for risk factors) for IMT 1.12 vs. 0.88
mm  4.8 (2.5–9.4); history of prior MI or stroke
did not significantly affect the increased RR
Increased carotid IMT was an independent
predictor of future MI.
Rosval et al. (58) 5,163 subjects (58 yrs) 7 yrs (median) Fatal and nonfatal stroke Adjusted HR was 2.54 (1.20–5.40) for IMT 0.81 vs.
0.69 mm and 1.26 (0.76–2.10) for the presence
vs. absence of carotid plaque
Carotid IMT was associated with incident stroke
independent of CV risk factors and carotid
plaque.
Lorenz et al. (59) 5,056 subjects (19–90 yrs) 4.2 yrs MI, stroke, combined end
point (MI, stroke, or death)
HR (adjusted for risk factors) for IMT 0.79 vs. 0.63
mm was 1.8 (0.97–3.4), 1.8 (0.64–5.2), and 1.8
(1.1–3.2) for MI, stroke, and the combined end
point, respectively
Increased carotid IMT independently predicted
CV events. The predictive value of increased
IMT seemed to be higher in the younger
(50 yrs) individuals.
Mean age (in parentheses) and follow-up are shown unless indicated otherwise.
DBP  diastolic blood pressure; MI  myocardial infarction; SBP  systolic blood pressure; other abbreviations as in Table 1.
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Arterial Ultrasonography and Tonometry April 3, 2007:1413–26therosclerosis (82,83). The predictive value of carotid
laques may be greater in patients with known cardiovas-
ular disease, whereas carotid IMT may be a better prog-
ostic marker in asymptomatic individuals. However, in a
ecent study (84), both carotid IMT and plaque were
ndependently predictive of stroke risk, and the predictive
alue of IMT was higher in the absence than in the presence
f plaque. In another recent study (58) of 5,163 apparently
ealthy middle-aged Swedish men and women, carotid
MT was associated with incident stroke, even after adjust-
ent for presence of carotid plaque and conventional risk
actors.
Ultrasonographic measurement of carotid IMT is a safe,
nexpensive, and reproducible measure of atherosclerotic
urden associated with prevalent and incident cardiovascu-
ar disease. Carotid IMT also can be used as a marker of
fficacy of therapies intended to achieve regression of
therosclerosis (85). Integration of carotid IMT measure-
ent into routine cardiovascular risk assessment may im-
rove risk stratification of individual subjects. The Ameri-
an Heart Association has concluded that among
symptomatic persons 45 years old, measurement of
arotid IMT in experienced laboratories could be considered
or further clarification of CHD risk (86). Automated
omputerized edge-detection software (87,88) and intravas-
ular contrast agents (89) may decrease variability and
mprove precision in IMT measurement. Development of
uidelines for quality control, standardization of measure-
ents, and establishment of thresholds for different risk
ategories will help optimize the use of carotid IMT in
linical practice.
rterial Tonometry for the
ssessment of Arterial Stiffness
rterial stiffening is a manifestation of arteriosclerosis, a
rocess characterized by thickening and loss of elasticity of
he arterial wall. Capacitance and conduit arteries are
redominantly affected, and histopathological features in-
lude fractured and damaged elastin fibers and increased
ollagen deposition (90). Not only is increased arterial
tiffness a marker of vascular aging, it also predicts target-
rgan damage and cardiovascular events. Increased arterial
tiffness impairs the cushioning function of the central
rterial reservoir with adverse consequences for cardiac
erformance and organ perfusion. The resulting hemody-
amic abnormalities (e.g., increased systolic blood pressure
BP] and pulse pressure and reduced diastolic BP) increase
ardiovascular morbidity and mortality (91–93). Systolic
ypertension increases cardiac workload and leads to myo-
ardial hypertrophy (94), whereas reduced diastolic BP may
ompromise coronary perfusion and increase vulnerability to
schemia (95). Stiffening of the aorta and its major branches
ay reduce or eliminate the normal elastic gradient between
he central and peripheral segments of the arterial tree; the
esulting increase in distal transmission of pressure pulse tnergy is deleterious to the microvascular beds of many
rgans and tissues (96). The pulsatile stress associated with
ncreased pulse pressure may also induce arterial remodeling
97), contribute to plaque formation and progression
98,99), and alter hemodynamic forces acting on the plaque
urface, all of which could increase the propensity for plaque
upture (100).
Several indexes of arterial stiffness have been proposed
101,102). However, 2 measures have been studied exten-
ively: 1) the velocity of arterial pulse wave transmission
cross an arterial segment, and 2) analysis of the arterial
aveforms to estimate augmentation of systolic pressure by
eripheral wave reflection. Both measures may be assessed
onveniently and reproducibly by using commercially avail-
ble devices based on the principle of applanation tonometry
103).
ortic pulse wave velocity (aPWV). Because blood is a
oncompressible fluid, transmission of the arterial pressure
ave occurs along the arterial wall and is influenced by the
iomechanical properties of the arterial wall. The velocity of
he pressure wave transmission (pulse wave velocity [PWV])
rovides a robust estimate of arterial stiffness (104) and is
escribed by the Moens-Korteweg equation:
PWV(Yh ⁄ 2R)
here Y is the Young’s modulus of the arterial wall, h is wall
hickness, R is arterial radius at the end of diastole, and  is
lood density (102). Central arterial stiffness is most com-
only estimated by measuring carotid-femoral PWV
aPWV) because the common carotid and femoral arteries
re located superficially and because the distance between
hem spans most of the length of aorta, the arterial segment
articularly prone to stiffening. Applanation tonometry
vide infra) provides a convenient method for measuring
PWV, although Doppler ultrasonography (105) and mag-
etic resonance imaging (106) also may be used. The latter
llows accurate assessment of aortic length and provides
eparate estimates of PWV for the proximal and distal
egments of aorta (107), but cost and logistics hinder its use
s a screening tool. In healthy adults, aPWV generally
anges from 5 to 7 m/s (108).
Aortic PWV increases with age and with the cumulative
ffect of risk factors on arterial wall physiology and struc-
ure. Increased aPWV is associated with the presence and
xtent of atherosclerotic disease in the coronary arteries
109–112) and other vascular beds (113). Aortic PWV is
ssociated with cardiovascular risk factors (114–117) and
orrelates with estimates of cardiovascular risk based on
onventional risk factor algorithms (104). A growing body
f evidence indicates that aPWV itself may have prognostic
alue. Several studies have shown an independent and signif-
cant association between aPWV and cardiovascular events in
ifferent populations (118–124) (Table 3), including patients
ith end-stage renal disease (118), hypertension (120), and
he elderly (119,121).
Studies Evaluating the Association of Aortic Pulse Wave Velocity With Cardiovascular Events
Table 3 Studies Evaluating the Association of Aortic Pulse Wave Velocity With Cardiovascular Events
Reference Study Sample Follow-Up End Points Assessed Risk Estimate (95% Confidence Interval) Conclusion
Blacher et al. (118) 241 patients on hemodialysis
with ESRD (52 yrs)
72 months All-cause and CV mortality OR (adjusted for age, time on dialysis, DBP, and hemoglobin)
for aPWV 12.0 vs. 9.4 m/s: 5.4 (2.4–11.9) for all-
cause mortality and 5.9 (2.3–15.5) for CV mortality
aPWV was an independent predictor of all
cause and CV mortality in patients with
ESRD.
Meaume et al. (119) 141 subjects (70–100 yrs) 30 months CV mortality OR (adjusted for several factors including SBP and prior CV
disease)  4.6 (1.4–15.7) for aPWV 17.7 vs. 17.7 m/s
aPWV was the major independent
predictor of CV death.
Boutouyrie et al. (120) 1,045 asymptomatic
hypertensives (51 yrs)
5.7 yrs Fatal and nonfatal CHD
events, all CV events
Adjusted RR for CHD events  2.8 (1.3–5.9) for subjects in
the highest (12.3 m/s) vs. lowest (10.0 m/s) tertile of
aPWV; similar RR for all CV events
aPWV was a more powerful predictor of
events than Framingham risk score,
especially in subjects classified as
low-risk.
Sutton-Tyrrell et al. (121) 2,488 community-based
subjects (73 yrs)
4.6 yrs Total mortality, fatal and
nonfatal CV events
Unadjusted RR for the highest vs. lowest quartiles of aPWV
 1.7 (1.2–2.5) for all-cause mortality, 2.3 (1.2–4.3) for
CV mortality, 1.5 (1.1–2.1) for CHD, and 3.6 (1.8–7.2) for
stroke
Increased aPWV was associated with
elevated risk of CHD, stroke, and all CV
events, even after adjustment for age,
gender, race, and SBP.
Laurent et al. (122) 1,980 patients with essential
hypertension (50 yrs)
112 months All-cause and CV mortality Adjusted OR for a 5 m/s increase in aPWV  1.3 (1.04–1.7)
for all-cause mortality and 1.5 (1.1–2.1) for CV mortality
aPWV was associated with all-cause and
CV mortality, independent of previous
CV disease, age, heart rate, or
diabetes.
Willum-Hansen et al. (123) 1,678 subjects (40–70 yrs),
no prior MI or stroke
9.4 yrs (median) Fatal and nonfatal
CHD events, stroke,
CV death
HR per 1-SD increment in aPWV  1.2 (1.01–1.4) for CV
mortality, 1.2 (1.0–1.4) for CHD, and 1.2 (1.04–1.3) for
composite end point
aPWV was a predictor of CV outcome in a
Danish population, independent of age,
gender, BMI, smoking, alcohol intake,
and mean BP.
Mattace-Raso et al. (124) 2,835 apparently healthy
subjects (72 yrs)
CHD, 4.1 yrs;
stroke, 3.2 yrs
Fatal and nonfatal
CV events
HR of CV disease (adjusted for risk factors, carotid IMT, ABI,
and pulse pressure) for the highest vs. lowest tertile of
aPWV  1.9 (1.2–3.2)
aPWV provided prognostic information
about CHD and stroke incremental to
that provided by risk factors, pulse
pressure, and measures of
atherosclerosis.
Mean age (in parentheses) and follow-up duration are shown unless indicated otherwise.
aPWV  aortic pulse wave velocity; BMI  body mass index; ESRD  end-stage renal disease; other abbreviations as in Tables 1 and 2.
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Arterial Ultrasonography and Tonometry April 3, 2007:1413–26Two recent studies have shown that aPWV provides
ncremental information about cardiovascular risk in asymp-
omatic individuals from the general population. In a
ommunity-based study of 1,678 Danes (123), aPWV
redicted incident cardiovascular events over a median
ollow-up period of 9.4 years. After adjustment for conven-
ional risk factors and average 24-h ambulatory BP, a
.4-m/s increase in aPWV was associated with a 16% to
0% increase in the risk of an adverse cardiovascular event.
n the Rotterdam Study (124), aPWV was a predictor of
HD and stroke, independent of conventional risk factors,
easures of atherosclerosis (carotid IMT and ankle-brachial
ndex), and pulse pressure. The age- and gender-adjusted
azard ratio for incident cardiovascular disease in subjects
ith aPWV in the highest tertile compared to those with
PWV in the lowest tertile was 2.40 (95% confidence
nterval 1.51 to 3.83).
To summarize, aPWV is a robust measure of central
rterial stiffness that may be a useful adjunct to cardiovas-
ular risk stratification. A recent consensus document (125)
escribed aPWV as the gold-standard measure of arterial
tiffness. Analogous to carotid IMT, aPWV also could be
sed to assess vascular age. The case for incorporating
PWV into routine clinical practice is strengthened by the
vidence supporting its independent prognostic value and
he availability of user-friendly devices for rapid, reliable,
nd reproducible measurement.
ulse wave analysis. Pulse wave analysis is based on the
rinciple that the forward-moving pressure wave generated
ith each cardiac pulse is partially reflected back toward the
orta at points of impedance mismatch along the arterial
ree (bifurcations, branch points, arterioles, and other sites
f discontinuity in arterial elasticity); this reflection in-
reases (augments) the central aortic pressure (102). Appla-
ation tonometry is a simple and reproducible method of
ulse wave analysis. The technique involves partial flatten-
ng (applanation) of a superficial artery against an underly-
ng bone using a handheld external pressure sensor; the
ensor eliminates tangential pressures and determines pres-
ure within the artery (102). A correctly obtained noninva-
ive pressure waveform is virtually identical to a waveform
ecorded by intra-arterial transducers (126,127). The radial
rtery pressure waveform is used to derive a central aortic
ressure waveform using a mathematical transfer function
hat has been validated under several different conditions
128–131), although some investigators have questioned the
eneralizability of the transfer function (132–135). Tonom-
try of the carotid artery (136) may obviate the need of a
ransfer function but requires a higher degree of technical
xpertise, particularly in obese subjects (137).
Analysis of arterial pulse waveforms provides information
bout several hemodynamic characteristics related to arterial
ave reflection. Augmentation pressure is defined as the
egree of augmentation of central systolic BP by the
eflected pressure wave. It is generally expressed as a fraction
f the central pulse pressure (aortic augmentation index bAIx]), and it is affected by several factors, including the
elocity of the reflected wave. When arteries are relatively
ompliant (e.g., in a young healthy adult), PWV is low; the
eflected wave arrives at the ascending aorta after closure of
he aortic valve and augments diastolic BP, thereby increas-
ng coronary perfusion. With increasing arterial stiffness,
he reflected wave is transmitted at a higher velocity and
rrives in systole, resulting in augmentation of systolic
ressure, increased cardiac workload, loss of augmentation
f diastolic pressure, and decreased coronary perfusion.
hereas aPWV represents a measure of aortic stiffness, AIx
eflects the overall interaction between the arterial tree and
he left ventricle (138).
Like carotid IMT and aPWV, AIx has been proposed as
measure of vascular age, albeit only in individuals younger
han 60 years (139). This is because AIx plateaus at or may
ven decrease after the age of 60 (96,139,140). The decrease
n AIx in older individuals could be caused by a proportion-
lly greater effect of the reflected wave in reducing flow at
he aortic valve than in augmenting the systolic BP in the
orta (141). Further, the preferential increase in central
rterial stiffness with aging and resulting changes in the
ormal centrifugal gradient of arterial stiffness may result in
educed amplitude, despite earlier timing of pressure wave
eflection, and decrease AIx (96).
Higher AIx is associated with increased left ventricular
ass in normotensive (142) and hypertensive adults (143),
ith lower cardiorespiratory fitness in asymptomatic men
144), and with lower walking distance in patients with
eripheral arterial disease (145). The AIx has also been
ssociated with higher C-reactive protein levels in asymp-
omatic adults (146,147) and with several cardiovascular risk
actors (148–152). However, AIx is lower in men compared
ith women (102), it is inversely related to body mass index
147,153), and it may not be a reliable measure of arterial
tiffness in diabetic patients (154–156).
Cross-sectional studies have shown AIx to be associated
ith the presence and extent of angiographic coronary artery
isease in patients with end-stage renal disease (111) and in
en 60 years of age undergoing diagnostic coronary
ngiography (157). Whether AIx is associated with cardio-
ascular risk in community-based cohorts is not known,
lthough several small studies have also shown AIx to be
redictive of adverse cardiovascular events in select popula-
ions (158–162) (Table 4), such as patients with end-stage
enal failure (158), patients with angiographically docu-
ented coronary artery disease (161), and patients under-
oing coronary revascularization (159,160). A recent study
id not find AIx to be predictive of cardiovascular events in
lderly hypertensive women (162).
Pulse wave analysis also can be used to estimate central
ystolic and pulse pressures from the radial artery-derived
ortic pressure waveform. Because of progressive amplifica-
ion of the pressure waveform from the central arteries to
he peripheral arteries, systolic BP and pulse pressure from
rachial artery cuff measurements may not accurately reflect
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April 3, 2007:1413–26 Arterial Ultrasonography and Tonometryhe corresponding pressures in the proximal aorta. Further-
ore, with age-related changes in arterial stiffness and wave
eflection, there is a disproportionate increase in central BP
hen compared with peripheral systolic and pulse pressures.
lthough sphygmomanometric measurements of brachial
rtery BP are well-established markers of cardiovascular
isk, these are surrogates for the more important central BP
o which the left ventricle is exposed. Recent reports suggest
hat central rather than brachial systolic BP is more relevant
o left ventricular afterload (102) and may therefore be a
etter marker of cardiovascular risk (139,163–165).
Cuff BP measurements may also underestimate the re-
uction in aortic BP with vasodilator therapy because these
rugs specifically affect the tone of the muscular arteries
ithout directly affecting the larger elastic arteries. The
esulting changes in pressure wave reflection may produce
ower central arterial systolic pressure than would be pro-
ected from the brachial pressure (measured by the cuff
ethod), and thus, vasodilator therapy may seem to lead to
ardiovascular benefits beyond BP control (166,167). Re-
ults from the recently reported CAFE (Conduit Artery
unction Evaluation) study (168) support this hypothesis.
n this study of 2,073 patients (ages 40 to 79 years) with
ntreated hypertension and no known cardiovascular dis-
ase, treatment with amlodipine with or without perindopril
roduced a significantly greater reduction in central aortic
ystolic and pulse pressures when compared with treatment
ith atenolol with or without thiazide, despite similar
eductions in brachial BP. Post-hoc analysis showed that
oth central aortic and peripheral pulse pressures were
redictive of the composite end point of cardiovascular
vents, revascularization procedures, and development of
enal insufficiency.
In summary, measurement of arterial stiffness using
onometry is a potentially useful adjunct to cardiovascular
isk stratification. Commercial tonometric devices are now
vailable; they can be used to obtain aPWV as well as to
cquire arterial pressure waveforms in an office setting.
urther, analysis of the radial artery-derived aortic pressure
aveform provides estimates of central aortic pressures that
ay be superior to cuff-derived measurements at the brachial
rtery as a guide to antihypertensive therapy. The information
btained from pulse wave analysis may be used to improve
haracterization of hemodynamic patterns and to generate
ndexes of ventricular–vascular interaction that were previously
ossible only with invasive arterial catheterization.
omparative Value of
oninvasive Testing Modalities
he arterial tests discussed in this review assess different
spects of arterial function and structure and are not
trongly correlated with each other; for example, brachial
rtery FMD correlates weakly with carotid IMT (169–171)
and with measures of arterial stiffness (171,172). PreviousSt
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Arterial Ultrasonography and Tonometry April 3, 2007:1413–26tudies have shown that carotid plaque burden and brachial
rtery FMD independently and additively predict occur-
ence of cardiovascular events (20) and that aPWV may be
predictor of CHD and stroke, independent of carotid
MT (124). Thus, different arterial tests may provide
omplementary information about arterial structure and
unction, and a combination of the tests might be superior
o any single test used alone. Further, because some arterial
hanges (e.g., impaired FMD) may be discernible earlier
han others (e.g., increase in carotid IMT or aPWV), an
bsence of abnormality in one testing domain would not
ule out an abnormality in other domains.
The relative utility of various modalities and tests as
djuncts to cardiovascular risk assessment depends on sev-
ral factors. Tonometry has an advantage over ultrasonog-
aphy in that it can be performed after minimal training
sing a relatively low-cost portable device, whereas ultra-
ound assessment of IMT and FMD require relatively
xpensive equipment and considerable operator skill. Ca-
otid IMT and aPWV are predictive of cardiovascular
vents in community-based cohorts, independent of con-
entional risk factors, whereas brachial artery FMD and AIx
ave been shown to be associated with cardiovascular events
n select groups of patients.
ummary
lthough office-based assessment of cardiovascular risk
sing conventional risk factor algorithms is important for
nitial risk stratification, it may not always answer the key
uestions of whether and how aggressively an asymptomatic
ndividual should be treated. Identification of preclinical
lterations in arterial function and structure may refine
Figure 2 A Proposed Algorithm Incorporating Arterial Testing in
Arterial ultrasonography and tonometry may be useful in refining estimates of coroardiovascular risk stratification and decrease the chances of
isclassification of cardiovascular risk. Arterial ultrasonog-
aphy and tonometry are 2 promising testing modalities in
his regard. For noninvasive tests of arterial function and
tructure to be incorporated into clinical practice, measure-
ent protocols need to be standardized, quality control
rocedures established, and risk-defining threshold values
dentified. Further technological advances might improve
eproducibility and decrease operator-dependence, making
hese tests more resource-efficient and potentially more
idely available.
Noninvasive tests should be performed solely to improve
isk assessment; they should supplement (but not replace)
he standard risk assessment algorithms and should not be
sed to make a diagnosis of cardiovascular disease. A
otential algorithm for noninvasive arterial testing (Fig. 2)
ncorporates both ultrasonography and tonometry in
ntermediate-risk and select low-risk subjects. Abnormal
ndings from one or more of these tests may change the risk
ategory assigned to an individual and could be used to
odify treatment thresholds and therapeutic targets for
isk-reduction therapy. Further, noninvasive testing may be
seful for longitudinal follow-up to monitor vascular disease
rogression and the effect of therapy. Detection and mon-
toring of early arterial abnormalities could become part of a
aradigm shift in the care of individuals at risk for cardio-
ascular events, with emphasis on prevention of such events.
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